Tüdőrák: vizsgálatok itt: Spanyolország
275 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 2026. november 17.. Ask the study team whether a trial fits you.
- No phaseTaking peopleA Study to Investigate Treatment Patterns and Effectiveness of Tislelizumab in European Patients With Resectable or Advanced Non-Small Cell Lung Cancer (NSCLC) and Small Cell Lung Cancer (SCLC)
- Where
- Córdoba, Jaén, Lugo, Segovia, Valencia
- Életkor
- 18 év and over
- People
- 440
- Run by
- BeOne Medicines
See details and how to joinNCT07652736 - 1. fázisTaking peopleKO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors
- Where
- Barcelona, Madrid, Sevilla
- Életkor
- 18 év and over
- People
- 300 worldwide
- Run by
- Kura Oncology, Inc.
See details and how to joinNCT06026410 · EU 2024-513285-19-00 - 3. fázisFelfüggesztveSafety and Efficacy of BNT327, an Investigational Therapy in Combination With Chemotherapy for Patients With Untreated Small-cell Lung Cancer
- Where
- Badajoz, Barcelona, Castello De La Plana, León, Madrid, Málaga, Sevilla, Torrejón de Ardoz, Valencia, Vigo, Zaragoza
- Életkor
- 18 év and over
- People
- 621 worldwide
- Run by
- BioNTech SE
See details and how to joinNCT06712355 · EU 2024-515765-34-00 - 2. fázisTaking peopleAn Open-Label, Phase 2b, Global Multicenter Cohort Trial to Assess the Safety and Efficacy of Zipalertinib in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Exon 20 Insertion and Uncommon/Single or Compound Epidermal Growth Factor Receptor Mutations
- Where
- A Coruna, Barcelona, Jaén, L'Hospitalet de Llobregat, Madrid, Málaga
- Életkor
- 18 év and over
- People
- 117 worldwide
- Run by
- Taiho Oncology Inc.
See details and how to join2023-503865-48-00 - 2/3. fázisNot yet taking people in SpanyolországIZABRIGHT-Lung01: Study of Izalontamab Brengitecan (BMS-986507) versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer after failure of EGFR TKI Therapy
- Where
- Barcelona, Madrid, Majadahonda, Málaga, Sevilla, Valencia, Zaragoza
- Életkor
- 18 év and over
- People
- 173 worldwide
- Run by
- Bristol-Myers Squibb Services Unlimited Company
See details and how to join2025-521908-22-00 - 1/2. fázisTaking peopleA Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies
- Where
- Barcelona, L'Hospitalet de Llobregat, Madrid, Málaga, Pamplona
- Életkor
- 18 év and over
- People
- 460 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT05123482 · EU 2022-502759-70-01 - 1/2. fázisTaking peoplePhase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies
- Where
- Barcelona, Madrid, Pamplona, Valencia
- Életkor
- 18 év and over
- People
- 554 worldwide
- Run by
- Institut de Recherches Internationales Servier
See details and how to joinNCT05786924 · EU 2025-523474-16-00 - 3. fázisFelfüggesztveA Study to Assess Zipalertinib Versus Placebo in Participants With Early Stage NSCLC With Uncommon EGFR Mutations, Following Complete Tumor Resection
- Where
- Badalona, Barcelona, Granada, Las Palmas de Gran Canaria, Lugo, Madrid, Majadahonda, Málaga, Palma, Reus, Sabadell, Sevilla, Valencia
- Életkor
- 18 év and over
- People
- 360 worldwide
- Run by
- Taiho Oncology, Inc.
See details and how to joinNCT07128199 · EU 2025-521775-31-00 - 2. fázisNot yet taking people in SpanyolországA Study to Assess The Safety and Tolerability of Pumitamig-Based Therapy Administered Before Surgery in Participants With Early-Stage Non-Small Cell Lung Cancer (ROSETTA Lung-220)
- Where
- Barcelona, Majadahonda, Málaga
- Életkor
- 18 év and over
- People
- 80 worldwide
- Run by
- Bristol-Myers Squibb
See details and how to joinNCT07871214 - 1. fázisTaking peopleA Study of ZL-1310 in Patients with Small Cell Lung Cancer to Find a Suitable Dose and to Test How Different Doses of ZL-1310 are Tolerated by the Body and How the Body Absorbs, Distributes, Metabolizes and Excretes ZL-1310
- Where
- Barcelona, Madrid, Málaga, Pozuelo de Alarcón, Sevilla, Valencia
- Életkor
- 18 év and over
- People
- 80
- Run by
- Zai Lab (US) LLC
See details and how to join2024-514446-36-00 - 1. fázisTaking peopleStudy of Elironrasib (RMC-6291) and Daraxonrasib (RMC-6236) With Other Anti-Cancer Agents in Patients With RAS G12C-Mutated NSCLC - Subprotocol A
- Where
- A Coruña, Badalona, Barcelona, Madrid, Málaga, Pamplona, Sevilla, Valencia
- Életkor
- 18 év and over
- People
- 330 worldwide
- Run by
- Revolution Medicines Inc.
See details and how to join2023-509571-16-00 - 1/2. fázisTaking peopleA Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors
- Where
- Barcelona, Logroño, Madrid, Pozuelo de Alarcón, Valencia
- Életkor
- 18 év and over
- People
- 1438 worldwide
- Run by
- BioNTech SE
See details and how to joinNCT07070232 · EU 2024-517261-16-00 - 2. fázisTaking peopleSymbiotic-Lung-14: A Study to Learn About the Study Medicine Called PF08634404 in Combination With Chemotherapy in Adult Participants With Transformed Small Cell Lung Cancer
- Where
- Barcelona, L'Hospitalet de Llobregat, Madrid, Sevilla
- Életkor
- 18 év and over
- People
- 40 worldwide
- Run by
- Pfizer
See details and how to joinNCT07476287 · EU 2025-524686-24-00 - 3. fázisTaking peopleSymbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
- Where
- Barcelona, Elche, Girona, Granada, Huelva, Jerez de la Frontera, Las Palmas de Gran Canaria, L'Hospitalet de Llobregat, Madrid, Málaga, Palma, Santiago de Compostela, Sevilla, Toledo, Torrejón de Ardoz, Valencia, Zaragoza
- Életkor
- 18 év and over
- People
- 1410 worldwide
- Run by
- Pfizer
See details and how to joinNCT07222566 · EU 2025-523461-17-01 - 2/3. fázisTaking peopleSymbiotic-Lung-04: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Extensive-Stage Small Cell Lung Cancer
- Where
- Barcelona, Jaén, Jerez de la Frontera, Madrid
- Életkor
- 18 év and over
- People
- 550 worldwide
- Run by
- Pfizer
See details and how to joinNCT07226999 · EU 2025-523522-41-00 - 1/2. fázisTaking peopleSymbiotic-Lung-20: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Different Anticancer Agents in Advanced Cancers
- Where
- Barcelona, Cadiz, Granada, Jaén, Jerez de la Frontera, Madrid, Málaga, Seville, Valencia
- Életkor
- 18 év and over
- People
- 162 worldwide
- Run by
- Pfizer
See details and how to joinNCT07227298 · EU 2025-523526-40-00 - 2. fázisNot yet taking people in SpanyolországSymbiotic-Lung-10: A Study to Learn About PF-08634404 Alone or in Combination in Early-stage or Locally Advanced NSCLC
- Where
- Barcelona, Madrid, Majadahonda, Zaragoza
- Életkor
- 18 év and over
- People
- 120 worldwide
- Run by
- Pfizer
See details and how to joinNCT07489066 · EU 2025-524825-42-00 - 1/2. fázisTaking peoplePhase 1/2 Multicenter, Open-label, Dose-escalation Study of IDP- 121 in Patients With Platinum-resistant Small Cell Lung Cancer (MYCrocytic)
- Where
- Barcelona, Las Palmas de Gran Canaria, Madrid, Málaga, Murcia, Pamplona, Santa Cruz de Tenerife, Valencia
- Életkor
- 18 év and over
- People
- 60
- Run by
- IDP Discovery Pharma S.L.
See details and how to joinNCT07864207 - 3. fázisTaking peopleA Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants with Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
- Where
- Barcelona, Las Palmas de Gran Canaria, L'Hospitalet de Llobregat, Madrid, Málaga, Palma, Pamplona, Santander, Sevilla, Valencia
- Életkor
- 18 év and over
- People
- 282 worldwide
- Run by
- F. Hoffmann-La Roche AG
See details and how to join2024-518365-10-00 - 2. fázisTaking peopleA Study of Zipalertinib in Patients With Advanced Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions or Other Uncommon Mutation.
- Where
- Barcelona, Jaén, Madrid, Málaga
- Életkor
- 18 év and over
- People
- 220 worldwide
- Run by
- Taiho Oncology, Inc.
See details and how to joinNCT05967689 - 1/2. fázisTaking peopleA Study to Evaluate the Safety and Efficacy of Gocatamig (MK-6070) and Ifinatamab Deruxtecan (I-DXd) in Participants With Relapsed/Refractory Extensive-Stage Small Cell Lung Cancer (MK-6070-002)
- Where
- Barcelona, L'Hospitalet de Llobregat, Madrid, Málaga
- Életkor
- 18 év and over
- People
- 327 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT06780137 · EU 2024-517926-25-00 - 1/2. fázisTaking peopleStudy of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies
- Where
- A Coruña, Barcelona, Málaga, Pozuelo de Alarcón, Sant Cugat del Vallès, Sevilla
- Életkor
- 18 év to 130 év
- People
- 695 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT05417594 · EU 2023-504984-17-00 - 1/2. fázisTaking peoplePhase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors
- Where
- Barcelona, Madrid, Málaga
- Életkor
- 18 év to 130 év
- People
- 622 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT05797168 · EU 2022-502576-23-00 - 1. fázisTaking peoplePhase 1 Study of OP-3136 in Advanced or Metastatic Solid Tumors
- Where
- Barcelona, Madrid
- Életkor
- 18 év and over
- People
- 180 worldwide
- Run by
- Olema Pharmaceuticals, Inc.
See details and how to joinNCT06784193 - 2/3. fázisTaking peopleA Study to Assess Adverse Events, Change in Disease Activity of Intravenous Telisotuzumab Adizutecan in Combination With Osimertinib as First-Line Treatment in Adult Participants With Locally Advanced Unresectable or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer
- Where
- Barcelona, Madrid, Valencia
- Életkor
- 18 év and over
- People
- 854 worldwide
- Run by
- AbbVie
See details and how to joinNCT07005102